|
Post by slugworth008 on May 9, 2018 8:34:34 GMT -5
2.2 millions dollar upfront payment is disappointing. 2.2 million is friggen peanuts. IMO But given the way things have been going it's better than nothing...and it IS more than anything we've seen from the stoners at RLS.
|
|
|
Post by celo on May 9, 2018 8:37:03 GMT -5
Cipla is the fourth biggest pharmaceutical company in India. Not bad
|
|
|
Post by mnkdfann on May 9, 2018 8:42:45 GMT -5
|
|
|
Post by seanismorris on May 9, 2018 8:43:31 GMT -5
I hope things move faster than In Brazil...
2.2 million probably only covers the overhead of dealing with the Indian partner...
The Brazil deal is probably costing MannKind money with zero return (to date)...
|
|
|
Post by wgreystone on May 9, 2018 8:43:53 GMT -5
drugs in India is usually 1/10 of price in U.S. Looking forward to a deal with China. We should at least get $20m upfront.
|
|
|
Post by uvula on May 9, 2018 8:44:46 GMT -5
|
|
|
Post by cjm18 on May 9, 2018 8:50:08 GMT -5
drugs in India is usually 1/10 of price in U.S. Looking forward to a deal with China. We should at least get $20m upfront. Why 20?
|
|
|
Post by sportsrancho on May 9, 2018 8:57:34 GMT -5
|
|
|
Post by kc on May 9, 2018 8:58:26 GMT -5
Interesting company with great depth in developing countries. they mainly specialize in Generic drugs but this might be a big deal as they also specialize in trying to get more into the inhaled drug business.
They have a link called Breathfree.
Focus on Inhaled drugs. This link shows many types of inhaler units. www.breathefree.com/inhalers-a-z
BreathFree A Cipla initiative www.breathefree.com/
Visit a Breathefree clinic to meet an educator, who will help you tackle your breathing problems.
Hmmm a bit like VDEX!
They are also in the Diabetes market already.
CIPLA Diabetes--- www.cipla.com/en/therapies/diabetes.html
|
|
|
Post by brentie on May 9, 2018 9:05:44 GMT -5
Will trials be required in India before approval is granted? "Yet Generex went silent about India in March 2009, after the drug regulators there decided that the initial approval of Oral-lyn violated the country's drug laws because the insulin spray had not been tested in local human clinical trials. The Indian government revoked Oral-lyn's approval, stopped new imports and ordered the product removed from Indian pharmacy shelves." www.thestreet.com/story/10718111/1/generex-what-happens-in-india-stays-in-india.html
|
|
|
Post by kc on May 9, 2018 9:12:07 GMT -5
drugs in India is usually 1/10 of price in U.S. Looking forward to a deal with China. We should at least get $20m upfront. China market is poor too. They biggest issue is getting into a market.
|
|
|
Post by goyocafe on May 9, 2018 9:15:15 GMT -5
I look forward to seeing "Dreamboat" added to the DPI section of the site.
|
|
|
Post by kc on May 9, 2018 9:26:47 GMT -5
CIPLA is already into PAH.....
www.cipla.com/en/therapies/respiratory.html
They have access and sell products in over 100 countries.
Cipla Respiratory products are available across the world, prescribed by physicians and consumed by patients in over 100 countries. A true testimony to our world-class quality.
|
|
|
Post by traderdennis on May 9, 2018 9:33:54 GMT -5
drugs in India is usually 1/10 of price in U.S. Looking forward to a deal with China. We should at least get $20m upfront. I expect zero dollars upfront for China but a hell of a lot of future insulin purchase commitments cancelled. I believe mnkd is on the hook for a high 8 digit or low 9 digits in total payments to amphastar
|
|
|
Post by kc on May 9, 2018 9:34:20 GMT -5
|
|